Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-367-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$181.28 million
Profitability
Miscellaneous
Employees437
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Glaukos (NYSE:GKOS) Frequently Asked Questions
What is Glaukos' stock symbol?
Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."
How were Glaukos' earnings last quarter?
Glaukos Corp (NYSE:GKOS) issued its earnings results on Wednesday, August, 7th. The medical instruments supplier reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The medical instruments supplier had revenue of $58.60 million for the quarter, compared to analyst estimates of $56.24 million. Glaukos had a negative return on equity of 5.77% and a negative net margin of 5.93%. Glaukos's quarterly revenue was up 35.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.15) earnings per share. View Glaukos' Earnings History.
When is Glaukos' next earnings date?
What guidance has Glaukos issued on next quarter's earnings?
Glaukos issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $226-231 million, compared to the consensus revenue estimate of $230.07 million.
What price target have analysts set for GKOS?
7 analysts have issued 1 year price objectives for Glaukos' shares. Their forecasts range from $66.02 to $90.00. On average, they anticipate Glaukos' stock price to reach $75.8367 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price. View Analyst Price Targets for Glaukos.
What is the consensus analysts' recommendation for Glaukos?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos.
What are Wall Street analysts saying about Glaukos stock?
Here are some recent quotes from research analysts about Glaukos stock:
- 1. According to Zacks Investment Research, "Glaukos is currently progressing with the U.S. commercial rollout of its next-generation iStent inject Trabecular Micro-Bypass device. It also initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Management is optimistic about the recent Avedro buyout. The company outperformed the industry year-to-date. With respect to quarterly results, Glaukos exited the second quarter on a tepid note. Also, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning." (9/12/2019)
- 2. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019)
Has Glaukos been receiving favorable news coverage?
Press coverage about GKOS stock has been trending negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Glaukos earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Glaukos.
Are investors shorting Glaukos?
Glaukos saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 3,770,900 shares, an increase of 16.4% from the July 15th total of 3,239,000 shares. Based on an average trading volume of 440,600 shares, the short-interest ratio is presently 8.6 days. Approximately 11.1% of the company's stock are short sold. View Glaukos' Current Options Chain.
Who are some of Glaukos' key competitors?
Some companies that are related to Glaukos include Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Cantel Medical (CMD), NuVasive (NUVA), ICU Medical (ICUI), Nevro (NVRO), Irhythm Technologies (IRTC) and Cardiovascular Systems (CSII).
What other stocks do shareholders of Glaukos own?
Who are Glaukos' key executives?
Glaukos' management team includes the folowing people:
- Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
- Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
- Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)
- Mr. Richard L. Harrison, Advisor (Age 62)
- Dr. Mory Gharib Ph.D., Co-Founder
When did Glaukos IPO?
(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Who are Glaukos' major shareholders?
Glaukos' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.72%), Baillie Gifford & Co. (7.76%), Brown Capital Management LLC (7.19%), BlackRock Inc. (6.99%), William Blair Investment Management LLC (6.63%) and Waddell & Reed Financial Inc. (3.24%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.
Which institutional investors are selling Glaukos stock?
GKOS stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Novo Holdings A S, Vanguard Group Inc., D. E. Shaw & Co. Inc., Granite Investment Partners LLC, William Blair Investment Management LLC, Invesco Ltd. and Cortina Asset Management LLC. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra, Joseph E Gilliam and William J Phd Link. View Insider Buying and Selling for Glaukos.
Which institutional investors are buying Glaukos stock?
GKOS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Nuveen Asset Management LLC, C WorldWide Group Holding A S, Brown Capital Management LLC, Point72 Asset Management L.P., Waddell & Reed Financial Inc., Renaissance Technologies LLC and BlackRock Inc.. View Insider Buying and Selling for Glaukos.
How do I buy shares of Glaukos?
Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Glaukos' stock price today?
One share of GKOS stock can currently be purchased for approximately $73.73.
How big of a company is Glaukos?
Glaukos has a market capitalization of $2.68 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos.
What is Glaukos' official website?
How can I contact Glaukos?
Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]
MarketBeat Community Rating for Glaukos (NYSE GKOS)
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
